Genetic Profile and Treatment of NSCLC
We recommend
Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition
More than 7 years – that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.
Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report…
New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference…
Articles on this topic
Targeted DNA Sequencing Helps Find Targeted Therapy for Patients with NSCLC
Gene sequencing has become a key tool in deciding the treatment for patients with non-small…
Third Generation Targeted Therapy for ROS1-Positive NSCLC
The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in…
Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC − Case Studies
Two remarkable case studies from authors at the Netherlands Cancer Institute Antoni van…
1
2
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Screening using NGS in patients with metastatic NSCLC – initial results from the ALK-positive cohort
- Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy
- Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
- Non-Small Cell Lung Cancer with Estrogen Receptors and ALK Positivity
- Progress on Lorlatinib – What's Next?
- Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases
Journal on this topic
Related topic